title: Chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study.
abstract: In the present work we analyzed the effect of the chronic administration of risperidone (2mg/kg over 65 days) on behavioural, morphological and molecular aspects in an experimental model of schizophrenia obtained by bilateral injection of ibotenic acid into the ventral hippocampus of new-born rats. Our results show that during their adult lives the animals with hippocampal lesions exhibit different alterations, mainly at behavioural level and in the gene expression of dopamine D(2) and 5-HT(2A) receptors. However, at morphological level the study performed on the prefrontal cortex did not reveal any alterations in either the thickness or the number of cells immunoreactive for c-Fos, GFAP, CBP or PV. Overall, risperidone administration elicited a trend towards the recovery of the values previously altered by the hippocampal lesion, approaching the values seen in the animals without lesions. It may be concluded that the administration of risperidone in the schizophrenia model employed helps to improve the altered functions, with no significant negative effects.
authors.affiliation: Institute for Neuroscience of Castilla y León, Salamanca, Spain; Department of Cell Biology and Pathology, University of Salamanca, Salamanca, Spain. orlandoc@usal.es
authors.forename: O
authors.initials: O
authors.lastname: Castellano
authors.forename: M
authors.initials: M
authors.lastname: Arji
authors.forename: C
authors.initials: C
authors.lastname: Sancho
authors.forename: J
authors.initials: J
authors.lastname: Carro
authors.forename: A S
authors.initials: AS
authors.lastname: Riolobos
authors.forename: V
authors.initials: V
authors.lastname: Molina
authors.forename: R
authors.initials: R
authors.lastname: Gómez-Nieto
authors.forename: José
authors.initials: J
authors.lastname: de Anchieta de Castro E Horta
authors.forename: M J
authors.initials: MJ
authors.lastname: Herrero-Turrión
authors.forename: D E
authors.initials: DE
authors.lastname: López
mesh_terms: D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001362:Avoidance Learning / Q000187:drug effects / Q000502:physiology; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000378:metabolism / Q000473:pathology*; D050882:CREB-Binding Protein / Q000378:metabolism; D002452:Cell Count; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D018690:Excitatory Amino Acid Agonists / Q000633:toxicity; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006120:Grooming / Q000187:drug effects; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology; D007051:Ibotenic Acid / Q000633:toxicity; D008297:Male; D010320:Parvalbumins / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D044402:Receptor, Serotonin, 5-HT2A / Q000235:genetics / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000235:genetics / Q000378:metabolism; D018967:Risperidone / Q000008:administration & dosage*; D012559:Schizophrenia / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D014150:Antipsychotic Agents; D018690:Excitatory Amino Acid Agonists; D005904:Glial Fibrillary Acidic Protein; D010320:Parvalbumins; D016760:Proto-Oncogene Proteins c-fos; D044402:Receptor, Serotonin, 5-HT2A; D017448:Receptors, Dopamine D2; D007051:Ibotenic Acid; D050882:CREB-Binding Protein; D018967:Risperidone